Aims: In a prospective, randomized, single, general surgery center trial, comparison of the safety and efficacy of two low molecular weight heparin (LMWH; anti-Xa heparin sodium and weight-adapted nadroparin calcium) regimens was made. Patients and Methods: Eleven hundred and ninety patients undergoing various elective and emergency operations were randomized to receive daily either a fixed dose of 3,000 IU anti-Xa heparin sodium or a variable body weight-dependent dose of nadroparin calcium (weight <50 kg, 2,050 IU anti-Xa (WHO); 51–80 kg, 3,075 UI; 81–100 kg, 4,100 UI, and >100 kg, 6,150 UI) once until discharge. The first injection was administered 2.5–6 h before elective and emergency operations, respectively. Patients with clinical suspicion of deep venous thrombosis (DVT) underwent phlebography. Patients with signs of pulmonary embolism (PE) were further investigated by a ventilation-perfusion scan. Results: Statistically, there were no significant differences in the incidence of clinically evident DVT, PE or LMWH-related complications between both prophylactic regimens. Only 4 of the total of 15 hemorrhagic complications (4 wound hematomas in the nadroparin calcium group) were not classified as clearly surgically related, Two DVTs were confirmed by phlebography (both in the nadroparin calcium group). PE was confirmed by ventilation-perfusion scans (1 fatal, 1 on autopsy) in 1 patient with heparin sodium and in 6 patients with nadroparin calcium. Conclusions: Both regimens were equally safe and the risk of clinically evident DVT and PE was similar.

Keywords:
Prevention of thromboembolic diseases, Weight-adapted nadroparin calcium, Heparin sodium, Pulmonary embolism, Deep venous thrombosis, Bleeding complications, Prospective randomized trial, Comparative study
1.
Collins R, Scrimgeour A, Yusuf S, Peto R: Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162–1173.
2.
Kalebo P, Anthmyr BA, Eriksson BI, Zachrisson BE: Phlebographic findings in venous thrombosis following total hip replacement. Acta Radiol 1990;31:259–263.
3.
Kakkar VV: Venous thrombosis today. Haemostasis 1994;24:86–104.
4.
Kakkar VV: Efficacy of low-dose heparin prophylaxis. Curr Ther Res Clin Exp 1975;18:6–20.
5.
Kakkar VV, Murray WJ: Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985;72:786–791.
6.
The European Fraxiparin Study (EFS) Group: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988;75:1058–1063.
7.
Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, Lindhagen A, Ljungner H, Ljungstrom KG: Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988;75:888–891.
8.
Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259–265.
9.
Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E: Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128–131.
10.
Bounameaux H: Low-molecular-weight heparins: A decade with the new class of antithrombotic agents. Vasa 1994;23:3–9.
11.
Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A: Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993;128:326–328.
12.
Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J: Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982;284:375–379.
13.
Kakkar VV, Adams PC: Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism – Can death from pulmonary embolism be prevented? J Am Coll Cardiol 1986;8:146B–158B.
14.
Haentjens P: Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 1996;27:385–390.
15.
Haas S, Flosbach CW: Prevention of postoperative thromboembolism with Enoxaparin in general surgery: A German multicenter trial. Semin Thromb Hemost 1993;19(suppl 1):164–173.
16.
Kakkar VV: Current recommendations in prevention of thrombosis in surgery. Blood Rev 1987;1:237–244.
17.
Kakkar VV: Prevention of fatal pulmonary embolism. Haemostasis 1993;23(suppl 1):42–50.
18.
ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–1103.
19.
Adolf J, Knee H, Roder JD, van dF, Siewert JR: Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery (in German). Dtsch Med Wochenschr 1989;114:48–53.
20.
Beumgartner A, Jacot N, Moser G, Krahenbuhl B: Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa 1989;18:152–156.
21.
Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G: Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204–208.
22.
Leyvraz PF, Bachmann F, Hoek J, Buller HR, Postel M, Samama M, Vandenbroek MD: Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543–548.
23.
Scher KS: Unplanned reoperation for bleeding. Am Surg 1996;62:52–55.
24.
Halonen P, Linko K, Wirtavuori K, Hastbacka J, Ikkala E: Evaluation of risk factors in intraoperative bleeding tendendy. Ann Chir Gynaecol 1987;76:298–302.
25.
Weale AE, Warwick DJ, Durant N, Prothero D: Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl 1995;77:35–37.
© 2000 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.